For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Blog
Virginia Postrel on Her Own Brush with Cost-Effective Drug Research
One letter writer argues that Herceptin was a poor example because "Multiple cost-effectiveness analyses have shown that, despite its high cost, Herceptin is both effective…
Op-Eds
Supreme Court Botches Preemption Case
SUPREME COURT BOTCHES PREEMPTION CASE…
Newsletter
AIG’s Tarnished Brand, The White House Vegetable Garden and Global Warming Negotiations
The damage to AIG’s corporate brand may hinder its ability to repay bailout loans from taxpayers. First Lady Michelle Obama announces the creation of a…
Newsletter
Toxic Assets, NIMBYs and Fish Pedicures
Treasury Secretary Timothy Geithner unveils a plan to sell off “toxic assets” as part of the federal bank bailout. The U.S. Chamber of Commerce launches…
Blog
Fishing for Rationality in the Beauty Salon
Thinking of getting one of those cool new “fish pedicures”? Well, you’d better act fast. 14 states have already banned the process. But a member…
Op-Eds
Needle and the Damage Done
The Supreme Court botches a drug preemption case.